

IN THE SPECIFICATION:

Please replace the Sequence Listing on pages 30-43 with the following text:

-- SEQUENCE LISTING

<110> Kyocera Corporation

Nishimura, Yoshihiko

Suzuki, Yoshihisa

Tanihara , Masao

<120> A Peptide and Osteogenetic Accelerator

<130> 81918-0001

<140> 09/439,779

<141> 1999-11-12

<160> 11

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (6) .. (6)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (7) .. (7)

<223> Xaa=Ile or Val

<220>

<221> MISC_FEATURE

<222> (10) .. (10)

<223> Xaa=Ala or Pro

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> Xaa=Ala or Val

<220>

<221> MISC_FEATURE

<222> (18)..(18)

<223> Xaa=Ser or Asn

<400> 1

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ser | Val | Asn | Ser | Xaa | Xaa | Pro | Lys | Xaa | Cys | Cys | Xaa | Pro | Thr | Glx |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | |
|-----|-----|-----|-----|--|
| Leu | Xaa | Ala | Ile | |
| | | | 20 | |

<210> 2

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (6) .. (6)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (7) .. (7)

<223> Xaa=Ile or Val

<220>

<221> MISC_FEATURE

<222> (10) .. (10)

<223> Xaa=Ala or Pro

<220>

<221> MISC_FEATURE

<222> (13) .. (13)

<223> Xaa=Ala or Val

<220>

<221> MISC_FEATURE

<222> (18) .. (18)

<223> Xaa=Ser or Asn

<400> 2

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ser | Val | Asn | Ser | Xaa | Xaa | Pro | Lys | Xaa | Cys | Cys | Xaa | Pro | Thr | Glx |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | |
|-----|-----|-----|-----|-----|
| Leu | Xaa | Ala | Ile | Ser |
| | | | 20 | |

<210> 3

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (7) .. (7)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (8) .. (8)

<223> Xaa=Ile or Val

<220>

<221> MISC_FEATURE

<222> (11) .. (11)

<223> Xaa=Ala or Pro

<220>

<221> MISC_FEATURE

<222> (14) .. (14)

<223> Xaa=Ala or Val

<220>

<221> MISC_FEATURE

<222> (19) .. (19)

<223> Xaa=Ser or Asn

<400> 3

Asn Ser Val Asn Pro Glu Xaa Xaa Pro Lys Xaa Cys Cys Xaa Pro Thr

1 5 10 15

Glx Leu Xaa Ala Ile
20

<210> 4

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> Xaa=Ile or Val

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> Xaa=Ala or Pro

<220>

<221> MISC_FEATURE

<222> (14)..(14)

<223> Xaa=Ala or Val

<220>

<221> MISC_FEATURE

<222> (19)..(19)

<223> Xaa= Ser or Asn

<400> 4

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ser | Val | Asn | Pro | Glu | Xaa | Xaa | Pro | Lys | Xaa | Cys | Cys | Xaa | Pro | Thr |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | |
|-----|-----|-----|-----|-----|-----|
| Glx | Leu | Xaa | Ala | Ile | Ser |
| | | | | | 20 |

<210> 5

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (4) .. (4)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (5) .. (5)

<223> Xaa=Ile or Val

<220>

<221> MISC_FEATURE

<222> (8) .. (8)

<223> Xaa=Ala or Pro

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> Xaa=Ala or Val

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa=Ser or Asn

<400> 5

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Asn | Ser | Xaa | Xaa | Pro | Lys | Xaa | Cys | Cys | Xaa | Pro | Thr | Glx | Leu | Xaa |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

Ala Ile

<210> 6

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (4) .. (4)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (5) .. (5)

<223> Xaa=Ile or Val

<220>

<221> MISC_FEATURE

<222> (8) .. (8)

<223> Xaa=Ala or Pro

<220>

<221> MISC_FEATURE

<222> (11) .. (11)

<223> Xaa=Ala or Val

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa=Ser or Asn

<400> 6

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Asn | Ser | Xaa | Xaa | Pro | Lys | Xaa | Cys | Cys | Xaa | Pro | Thr | Glx | Leu | Xaa |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

Ala Ile Ser

<210> 7

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (6) .. (6)

<223> Xaa=Ile or Val

<220>

<221> MISC_FEATURE

<222> (9) .. (9)

<223> Xaa=Ala or Pro

<220>

<221> MISC_FEATURE

<222> (12) .. (12)

<223> Xaa=Ala or Val

<220>

<221> MISC_FEATURE

<222> (17) .. (17)

<223> Xaa=Ser or Asn

<400> 7

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Asn | Pro | Glu | Xaa | Xaa | Pro | Lys | Xaa | Cys | Cys | Xaa | Pro | Thr | Glx | Leu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

Xaa Ala Ile

<210> 8

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa=Lys, Ser or Thr

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa=Ile or Val

<220>

<221> MISC_FEATURE

<222> (9) .. (9)

<223> Xaa=Ala or Pro

<220>

<221> MISC_FEATURE

<222> (12) .. (12)

<223> Xaa=Ala or Val

<220>

<221> MISC_FEATURE

<222> (17) .. (17)

<223> Xaa=Ser or Asn

<400> 8

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Asn | Pro | Glu | Xaa | Xaa | Pro | Lys | Xaa | Cys | Cys | Xaa | Pro | Thr | Glx | Leu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | |
|-----|-----|-----|-----|
| Xaa | Ala | Ile | Ser |
| | | | 20 |

<210> 9

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<400> 9

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ser | Val | Asn | Ser | Lys | Ile | Pro | Lys | Ala | Cys | Cys | Val | Pro | Thr | Glu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | |
|-----|-----|-----|-----|
| Leu | Ser | Ala | Ile |
| | | | 20 |

<210> 10

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<400> 10

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ser | Val | Asn | Ser | Ser | Ile | Pro | Lys | Ala | Cys | Cys | Val | Pro | Thr | Glu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | |
|-----|-----|-----|-----|
| Leu | Ser | Ala | Ile |
| | | | 20 |

<210> 11

<211> 20

<212> PRT

<213> Artificial

<400> 11

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Asn | Pro | Glu | Thr | Val | Pro | Lys | Pro | Cys | Cys | Ala | Pro | Thr | Gln | Leu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

Asn Ala Ile Ser --
20